ClinicalTrials.gg

Program

PKC-beta Inhibitor MS-553

Also written as “MS-553”, “MS-553, DS1” and “MS-553, DS2”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Macular Edema · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Furthest: phase 2, since Mar 24, 20186 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MingSight Pharmaceuticals31 open or runningphase 2since Mar 24, 2018Mar 24, 2018Sep 2028phase 2 · NCT06979076
Shenzhen MingSight Relin Pharmaceuticals21 open or runningphase 2since Feb 18, 2022Dec 3, 2019none ahead
MingSight Pharmaceuticals Pty10 open or runningphase 1since Mar 25, 2015Mar 25, 2015none ahead

Also a collaborator on its studies: Fountain Medical Development.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2015First study: phase 1 study in Safety and PK in Healthy VolunteersNew to MingSight Pharmaceuticals PtyMingSight Pharmaceuticals Pty · NCT02406989 · 32 enrolled · Australia
  2. Mar 24, 2018MingSight Pharmaceuticals’ first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to MingSight PharmaceuticalsMingSight Pharmaceuticals · NCT03492125 · 60 enrolled · United States
  3. Dec 3, 2019Shenzhen MingSight Relin Pharmaceuticals’ first study: phase 1 study in Macular EdemaNew to Shenzhen MingSight Relin PharmaceuticalsShenzhen MingSight Relin Pharmaceuticals · NCT04187443 · 45 planned · China
  4. Feb 18, 2022Phase 2 study in Leukemia, LymphoidShenzhen MingSight Relin Pharmaceuticals · NCT05272813 · 13 enrolled · China
  5. Jan 11, 2023Phase 2 study in RecurrenceMingSight Pharmaceuticals · NCT05720052 · 8 enrolled · China
  6. May 2, 2025Phase 2 study in Leukemia, B-CellMingSight Pharmaceuticals · NCT06979076 · 12 planned

Ahead

  1. Sep 2028Primary completion: phase 2 study in Leukemia, B-CellMingSight Pharmaceuticals · NCT06979076

TargetBeta

PRRT2 →read by rule
“An orally available inhibitor of the beta-isoform of protein kinase C (PKC), ”NCIt, by rule

Other programs on PRRT2

ProgramCompanyFurthest phaseStudies
darovasertibruleideaya-biosciencesphase 36

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06979076Leukemia, B-Cell2Not yet recruitingMingSight PharmaceuticalsSep 202812
NCT05720052Recurrence · China2TerminatedMingSight PharmaceuticalsNov 28, 20238
NCT05272813Leukemia, Lymphoid · China2TerminatedShenzhen MingSight Relin PharmaceuticalsNov 28, 202313
NCT04187443Macular Edema · China1RecruitingShenzhen MingSight Relin PharmaceuticalsOct 30, 202645
NCT03492125Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedMingSight PharmaceuticalsNov 28, 202360
NCT02406989Safety and PK in Healthy Volunteers · Australia1CompletedMingSight Pharmaceuticals PtyAug 201532

How it is read

Names in the registry

  • “MS-553”, 6 entries
  • “MS-553, DS1”, 1 entry
  • “MS-553, DS2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.